

# Sang Joon Shin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/167701/publications.pdf>

Version: 2024-02-01

134  
papers

2,889  
citations

201674

27  
h-index

214800

47  
g-index

135  
all docs

135  
docs citations

135  
times ranked

5290  
citing authors

#	ARTICLE	IF	CITATIONS
1	Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2022, 21, e78-e86.	2.3	3
2	Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma. <i>European Journal of Cancer</i> , 2022, 163, 55-65.	2.8	5
3	A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 95-95.	1.6	4
4	Suppression of DYRK1A/B Drives Endoplasmic Reticulum Stress-mediated Autophagic Cell Death Through Metabolic Reprogramming in Colorectal Cancer Cells. <i>Anticancer Research</i> , 2022, 42, 589-598.	1.1	1
5	Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors. <i>Cancers</i> , 2022, 14, 2659.	3.7	7
6	The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211132.	3.2	10
7	Oxaliplatin (3 months <i>v</i> 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07. <i>Journal of Clinical Oncology</i> , 2022, 40, 3868-3877.	1.6	6
8	Effect of more versus less frequent abdominopelvic computed tomography follow-up testing on overall survival in patients with stage II or III colon cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3604-3604.	1.6	0
9	Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steadyâ€State Pharmacokinetics of Vemurafenib in Patients With BRAF V600 Mutationâ€Positive Malignancies. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 39-45.	1.6	3
10	Autonomy is not but competence and relatedness are associated with physical activity among colorectal cancer survivors. <i>Supportive Care in Cancer</i> , 2021, 29, 1653-1661.	2.2	3
11	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Nonâ€Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1029-1039.	1.6	145
12	Ferroportin and FBXL5 as Prognostic Markers in Advanced Stage Clear Cell Renal Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2021, 53, 1174-1183.	3.0	2
13	A phase I dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2021, 39, 1335-1347.	2.6	1
14	ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. <i>Nature</i> , 2021, 594, 418-423.	27.8	64
15	Upfront chemotherapy and short-course radiotherapy with delayed surgery for locally advanced rectal cancer with synchronous liver metastases. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2814-2820.	1.0	2
16	2020 Korean guidelines for the management of metastatic prostate cancer. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 491-514.	1.7	5
17	Value of cabozantinib in the treatment of advanced metastatic clear cell renal cell carcinoma (ccRCC): Real-world data from a single Korean institution.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16578-e16578.	1.6	1
18	Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators. <i>Frontiers in Oncology</i> , 2021, 11, 659754.	2.8	6

#	ARTICLE	IF	CITATIONS
19	Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection. <i>World Allergy Organization Journal</i> , 2021, 14, 100553.	3.5	7
20	Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 47, 128226.	2.2	11
21	Patterns of Locoregional Recurrence after Radical Cystectomy for Stage T3-4 Bladder Cancer: A Radiation Oncologist's Point of View. <i>Yonsei Medical Journal</i> , 2021, 62, 569.	2.2	4
22	470â€¦A phase 1/2, open-label, dose escalation and expansion study of GI-101 as a single agent and in combination with a pembrolizumab, lenvatinib or local RT in advanced solid tumors (KEYNOTE-B59). , 2021, 9, A499-A499.		4
23	Deep-Learning-Based Natural Language Processing of Serial Free-Text Radiological Reports for Predicting Rectal Cancer Patient Survival. <i>Frontiers in Oncology</i> , 2021, 11, 747250.	2.8	1
24	Male sex and Breslow thickness are important risk factors for recurrence of localized melanoma in Korean populations. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1071-1079.	1.2	10
25	Objectively measured physical activity during chemotherapy in colon cancer patients. <i>Supportive Care in Cancer</i> , 2020, 28, 2597-2604.	2.2	2
26	Clinical features and KRAS mutation in colorectal cancer with bone metastasis. <i>Scientific Reports</i> , 2020, 10, 21180.	3.3	18
27	A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases. <i>Clinical Colorectal Cancer</i> , 2020, 19, e140-e150.	2.3	9
28	Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. <i>European Journal of Cancer</i> , 2020, 135, 31-38.	2.8	11
29	Clinical Significance of Preoperative Serum Carcinoembryonic Antigen Within the Normal Range in Colorectal Cancer Patients Undergoing Curative Resection. <i>Annals of Surgical Oncology</i> , 2020, 27, 2774-2783.	1.5	12
30	Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 61-70.	7.0	27
31	Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial. <i>Trials</i> , 2020, 21, 320.	1.6	5
32	First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5034-5034.	1.6	6
33	Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS591-TPS591.	1.6	9
34	Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy. <i>Cancer Research and Treatment</i> , 2020, 52, 730-738.	3.0	7
35	VEGF-A drives TOX-dependent T cell exhaustion in antiâ€“PD-1â€“resistant microsatellite stable colorectal cancers. <i>Science Immunology</i> , 2019, 4, .	11.9	148
36	Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients. <i>Frontiers in Oncology</i> , 2019, 9, 835.	2.8	32

#	ARTICLE	IF	CITATIONS
37	Treatment Outcomes of Re-irradiation in Locoregionally Recurrent Rectal Cancer and Clinical Significance of Proper Patient Selection. <i>Frontiers in Oncology</i> , 2019, 9, 529.	2.8	13
38	Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3000-3000.	1.6	40
39	KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (NCC-RCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4569-4569.	1.6	23
40	First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4570-4570.	1.6	14
41	First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.. <i>Journal of Clinical Oncology</i> , 2019, 37, 546-546.	1.6	42
42	Oxaliplatin-induced Peripheral Neuropathy, Symptoms, Distress and Quality of Life among Korean Patients with Gastrointestinal Cancer. <i>Asian Oncology Nursing</i> , 2019, 19, 204.	0.6	0
43	Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors. <i>Journal of Cancer Prevention</i> , 2019, 24, 48-53.	2.0	1
44	IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class II-Deficient Tumors. <i>Cancer Immunology Research</i> , 2018, 6, 685-695.	3.4	39
45	YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 255-266.	3.4	158
46	Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection. <i>Clinical Colorectal Cancer</i> , 2018, 17, e513-e518.	2.3	24
47	Mapping of lateral pelvic lymph node recurrences in rectal cancer: a radiation oncologist's perspective. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1119-1128.	2.5	7
48	The role of endoscopic evaluation for radiation proctitis in patients receiving intermediate-dose postoperative radiotherapy for rectal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 988-994.	1.3	3
49	CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer. <i>Yonsei Medical Journal</i> , 2018, 59, 588.	2.2	24
50	Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells. <i>Cancer Research</i> , 2018, 78, 5315-5326.	0.9	44
51	Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results from cohort A of KEYNOTE-427.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4500-4500.	1.6	78
52	Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma. <i>Cancer Research and Treatment</i> , 2018, 50, 1238-1251.	3.0	10
53	Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions. <i>Cancer Research and Treatment</i> , 2018, 50, 1378-1387.	3.0	12
54	Sunrise in melanoma management: Time to focus on melanoma burden in Asia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 423-427.	1.1	23

#	ARTICLE	IF	CITATIONS
55	A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 773-781.	2.6	4
56	IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours. <i>Nature Communications</i> , 2017, 8, 15776.	12.8	119
57	Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. <i>Oncology Letters</i> , 2017, 14, 2385-2392.	1.8	6
58	Quality of life among Korean gastrointestinal cancer survivors. <i>European Journal of Oncology Nursing</i> , 2017, 30, 15-21.	2.1	17
59	Reduced pelvic field sparing anastomosis for postoperative radiotherapy in selected patients with midâ€“upper rectal cancer. <i>Journal of Radiation Research</i> , 2017, 58, 559-566.	1.6	4
60	Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 227-235.	1.5	39
61	Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery. <i>BMC Cancer</i> , 2017, 17, 615.	2.6	9
62	Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort. <i>Cancer Research and Treatment</i> , 2017, 49, 44-53.	3.0	27
63	Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients. <i>American Journal of Cancer Research</i> , 2017, 7, 134-138.	1.4	6
64	Upfront Systemic Chemotherapy and Short-Course Radiotherapy with Delayed Surgery for Locally Advanced Rectal Cancer with Distant Metastases: Outcomes, Compliance, and Favorable Prognostic Factors. <i>PLoS ONE</i> , 2016, 11, e0161475.	2.5	21
65	Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. <i>British Journal of Cancer</i> , 2016, 115, 25-33.	6.4	129
66	Impact of p16 expression in oropharyngeal cancer in the postoperative setting: the necessity of re-evaluating traditional risk stratification. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 911-918.	1.3	7
67	High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2051-2059.	2.5	12
68	Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 928-935.	1.5	28
69	A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis. <i>Radiotherapy and Oncology</i> , 2016, 118, 369-374.	0.6	24
70	&lt;i>p16&lt;/i>; Hypermethylation and &lt;i>KRAS&lt;/i> Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 208-215.	3.0	11
71	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial. <i>Cancer Research and Treatment</i> , 2016, 48, 1210-1221.	3.0	11
72	Clinical Implications from a Single-Center Study of Colorectal Adenocarcinoma in Transplant Recipients. <i>Oncology</i> , 2015, 88, 195-200.	1.9	1

#	ARTICLE	IF	CITATIONS
73	Incorporation of Radiotherapy in the Multidisciplinary Treatment of Isolated Retroperitoneal Lymph Node Recurrence from Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 1520-1526.	1.5	24
74	A Randomized Phase 2 Study of Neoadjuvant Chemoradiation Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 1015-1022.	0.8	24
75	<i>Pinch</i> presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. <i>International Journal of Cancer</i> , 2015, 136, 2273-2283.	5.1	11
76	Novel Methods for Clinical Risk Stratification in Patients with Colorectal Liver Metastases. <i>Cancer Research and Treatment</i> , 2015, 47, 242-250.	3.0	8
77	Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine. <i>Cancer Research and Treatment</i> , 2015, 47, 781-789.	3.0	10
78	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2014, 32, 561-568.	2.6	2
79	Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 399-409.	2.5	7
80	High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients. <i>World Journal of Surgical Oncology</i> , 2014, 12, 232.	1.9	30
81	Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis. <i>Journal of Surgical Oncology</i> , 2014, 110, 214-221.	1.7	35
82	S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: Updated results from a phase 3 trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 3608-3608.	1.6	0
83	Assessment of efficiency and safety of the comprehensive Chemotherapy Assistance Program for ordering oncology medications. <i>International Journal of Medical Informatics</i> , 2013, 82, 504-513.	3.3	13
84	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. <i>Supportive Care in Cancer</i> , 2013, 21, 1751-1759.	2.2	38
85	Prognostic Value of Mucinous Histology Depends on Microsatellite Instability Status in Patients with Stage III Colon Cancer Treated with Adjuvant FOLFOX Chemotherapy: A Retrospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2013, 20, 3407-3413.	1.5	71
86	Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. <i>Investigational New Drugs</i> , 2013, 31, 1-13.	2.6	11
87	Quantitation and pharmacokinetics of 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene ( <i>U</i> 0126) in rat plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Separation Science</i> , 2013, 36, 239-245.	2.5	4
88	Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study. <i>Journal of Surgical Oncology</i> , 2013, 107, 613-618.	1.7	20
89	Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 853-860.	2.3	5
90	Changing treatment patterns in elderly patients with resectable colon cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 265-272.	1.1	8



#	ARTICLE	IF	CITATIONS
91	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 492-492.	1.6	1
92	A randomized phase II study of neoadjuvant chemoradiotherapy with 5-FU/leucovorin or irinotecan/S1 in patients with locally advanced rectal cancer.. Journal of Clinical Oncology, 2013, 31, 511-511.	1.6	1
93	Response Evaluation in Patients With Colorectal Liver Metastases: RECIST Version 1.1 Versus Modified CT Criteria. American Journal of Roentgenology, 2012, 199, 809-815.	2.2	77
94	Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience. BMC Cancer, 2012, 12, 471.	2.6	1
95	VIPoma that arose from the rectum in a 65-year-old male patient. International Journal of Colorectal Disease, 2012, 27, 1385-1386.	2.2	3
96	Implications of clinical risk score to predict outcomes of liver-confined metastasis of colorectal cancer. Surgical Oncology, 2012, 21, e125-e130.	1.6	8
97	A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and) Tj ETQq1 1 0.784314 rgBT /Over treated with chemotherapy. Investigational New Drugs, 2012, 30, 1501-1510.	2.6	18
98	Perfusion MRI for the prediction of treatment response after preoperative chemoradiotherapy in locally advanced rectal cancer. European Radiology, 2012, 22, 1693-1700.	4.5	83
99	Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial. Cancer Chemotherapy and Pharmacology, 2012, 69, 91-97.	2.3	2
100	A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. Investigational New Drugs, 2012, 30, 672-680.	2.6	20
101	Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis. Cancer Research and Treatment, 2012, 44, 43-49.	3.0	14
102	Prognostic significance of intermediate mucinous carcinoma in patients with microsatellite stable stage II or III colon cancer.. Journal of Clinical Oncology, 2012, 30, 3606-3606.	1.6	0
103	Mucinous histology to predict disease-free survival in microsatellite stable stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.. Journal of Clinical Oncology, 2012, 30, e14084-e14084.	1.6	0
104	A prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver metastasis.. Journal of Clinical Oncology, 2012, 30, e14072-e14072.	1.6	0
105	Thymidylate Synthase Gene Polymorphism Affects the Response to Preoperative 5-Fluorouracil Chemoradiation Therapy in Patients With Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 669-676.	0.8	31
106	Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Anti-Cancer Drugs, 2011, 22, 801-810.	1.4	14
107	Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer. Investigational New Drugs, 2011, 29, 1073-1080.	2.6	8
108	Brain metastases from colorectal carcinoma: prognostic factors and outcome. Journal of Neuro-Oncology, 2011, 101, 49-55.	2.9	81

#	ARTICLE	IF	CITATIONS
109	Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 991-999.	2.3	4
110	Upfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases. <i>Radiation Oncology</i> , 2011, 6, 99.	2.7	35
111	Comparison of diffusion-weighted MRI and MR volumetry in the evaluation of early treatment outcomes after preoperative chemoradiotherapy for locally advanced rectal cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 34, 570-576.	3.4	60
112	A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. <i>Cancer</i> , 2011, 117, 2050-2057.	4.1	42
113	DNA methylation predicts recurrence from resected stage III proximal colon cancer. <i>Cancer</i> , 2011, 117, 1847-1854.	4.1	139
114	Comparison of Long-Term Outcome between Doublet and Triplet Neoadjuvant Chemotherapy in Non-Metastatic Osteosarcoma of the Extremity. <i>Oncology</i> , 2011, 80, 107-117.	1.9	11
115	Efficacy of Oxaliplatin-Based Chemotherapy in Curatively Resected Colorectal Cancer with Liver Metastasis. <i>Oncology</i> , 2011, 81, 175-183.	1.9	18
116	A Phase II Study of a Combined Biweekly Irinotecan and Monthly Cisplatin Treatment for Metastatic or Recurrent Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 56-60.	1.3	3
117	Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 387-394.	2.5	41
118	A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. <i>Investigational New Drugs</i> , 2010, 28, 650-658.	2.6	21
119	The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study. <i>Radiation Oncology</i> , 2010, 5, 75.	2.7	27
120	A Case of Combined Hepatocellular-Cholangiocarcinoma with Favorable Response to Systemic Chemotherapy. <i>Cancer Research and Treatment</i> , 2010, 42, 235.	3.0	20
121	Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m <sup>2</sup> bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 29-35.	1.3	2
122	Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial. <i>Lung Cancer</i> , 2010, 70, 77-81.	2.0	14
123	Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. <i>Cancer Letters</i> , 2010, 288, 124-132.	7.2	34
124	Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2010, 95, 303-307.	0.6	26
125	Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer. <i>International Journal of Oncology</i> , 2009, 34, 787-96.	3.3	1
126	Benefits of Recurrent Colonic Stent Insertion in a Patient with Advanced Gastric Cancer with Carcinomatosis Causing Colonic Obstruction. <i>Yonsei Medical Journal</i> , 2009, 50, 296.	2.2	3



#	ARTICLE	IF	CITATIONS
127	Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 919-927.	2.3	6
128	Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 65, 27-32.	2.3	25
129	Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. <i>Cancer Letters</i> , 2008, 270, 269-276.	7.2	6
130	Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. <i>Acta Oncologica</i> , 2007, 46, 547-549.	1.8	1
131	The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 75-81.	2.3	10
132	Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 157-165.	2.3	13
133	Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 309-313.	2.3	11
134	Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children. <i>Cancer Research and Treatment</i> , 1970, 47, 9-17.	3.0	12